<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B675829B-3A07-47C2-AA9F-86C9F86DD6A6"><gtr:id>B675829B-3A07-47C2-AA9F-86C9F86DD6A6</gtr:id><gtr:name>Scottish Universities Life Sciences Alliance (SULSA)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C5F16D4F-F1DA-459E-B344-DC54C5E90C44"><gtr:id>C5F16D4F-F1DA-459E-B344-DC54C5E90C44</gtr:id><gtr:name>Jefferson Medical College</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E71BE209-CC55-4935-A1B7-188175235B1F"><gtr:id>E71BE209-CC55-4935-A1B7-188175235B1F</gtr:id><gtr:name>Institute of Translational Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B675829B-3A07-47C2-AA9F-86C9F86DD6A6"><gtr:id>B675829B-3A07-47C2-AA9F-86C9F86DD6A6</gtr:id><gtr:name>Scottish Universities Life Sciences Alliance (SULSA)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C5F16D4F-F1DA-459E-B344-DC54C5E90C44"><gtr:id>C5F16D4F-F1DA-459E-B344-DC54C5E90C44</gtr:id><gtr:name>Jefferson Medical College</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88285966-BD20-4E44-AF3E-0082C76926BB"><gtr:id>88285966-BD20-4E44-AF3E-0082C76926BB</gtr:id><gtr:name>Department of Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E71BE209-CC55-4935-A1B7-188175235B1F"><gtr:id>E71BE209-CC55-4935-A1B7-188175235B1F</gtr:id><gtr:name>Institute of Translational Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E0416AD8-4131-44FC-A547-39F780732240"><gtr:id>E0416AD8-4131-44FC-A547-39F780732240</gtr:id><gtr:name>Thomas Jefferson University</gtr:name><gtr:address><gtr:line1>Thomas Jefferson University</gtr:line1><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ECE36D59-B789-4BAC-8049-E268296471CD"><gtr:id>ECE36D59-B789-4BAC-8049-E268296471CD</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Marin</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A1966A61-F479-4250-9C7F-ECF6E4F59340"><gtr:id>A1966A61-F479-4250-9C7F-ECF6E4F59340</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Clark</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9026D809-A3A5-407F-9EBB-CFA20FD6CEAB"><gtr:id>9026D809-A3A5-407F-9EBB-CFA20FD6CEAB</gtr:id><gtr:firstName>Tessa</gtr:firstName><gtr:surname>Holyoake</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0900882"><gtr:id>6AE04D2E-39C9-480D-A178-384C2F46924C</gtr:id><gtr:title>A randomised phase 2 trial of IM versus HCQ/IM for patients with CML in MCyR with residual disease by Q-PCR</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900882</gtr:grantReference><gtr:abstractText>Patients who developed chronic myeloid leukaemia (CML) are currently treated with drugs called tyrosine kinase inhibitors (TKI), which bind to and inhibit the function of BCR/ABL, the abnormal protein found exclusively in CML cells. In the majority of cases these drugs convert CML from a rapidly progressive and fatal disease to a chronic condition where quality of life is maintained for at least 10 years on continuous drug therapy. However continuous drug therapy is expensive and associated with significant side effects for patients. Since BCR/ABL is the major survival and proliferative factor driving the development and progression of CML, when this protein is switched off by TKI the majority of CML cells die. The cells which fail to die in response to these drugs are either stem or bone marrow founder cells (CML in early phase) or cells showing other forms of drug resistance (CML in advanced phase). It is critical to find ways to kill CML stem cells as these cells are responsible for producing all the other cells that constitute the disease and without killing these cells CML cannot be cured. Our long term aims are to find combinations of drugs that can cure CML in early phase and to improve responses in advanced phase. We have recently shown that when CML cells, including stem cells, are exposed to TKI they induce a process called ?autophagy? in which, in simple terms, the cells begin to break down their own intracellular constituents to produce energy. By producing energy in this way they are able to survive the drug exposure. In preliminary studies (Journal of Clinical Investigation, in press) we have shown that the drug hydroxychloroquine (HCQ), which inhibits the process of autophagy, potentiates the effect of TKI in inducing death of CML cells, including stem cells. In this proposal we aim to lead a Phase 2 trial in which patients who have been on imatinib (standard TKI for CML) for 12 months, are tolerating it well and have experienced a partial response to treatment, will be randomised to either continue imatinib therapy or to take imatinib in combination with HCQ. The combination treatment will last 12 months and the study will investigate the safety of combining imatinib with HCQ and test whether the combination is more effective than imatinib alone.</gtr:abstractText><gtr:technicalSummary>Imatinib mesylate (IM) is standard therapy for CML. The main limitations of IM and second generation tyrosine kinase inhibitors (TKI) are development of resistance and instrinsic refractoriness of CML stem cells to these agents. Therefore, new therapeutic approaches that more effectively target CML stem cells and prevent the outgrowth of TKI-resistant cells are required. Our preliminary data (JCI in press) lead us to believe that autophagy is a major cause of TKI-resistance in CML stem cells. We have shown that IM induces autophagy in BCR/ABL+ cells, including primary CML stem cells. Suppression of autophagy in BCR/ABL+ cells using pharmcological inhibitors or siRNA-mediated knockdown of essential autophagy genes enhances cell death induced by IM in primary CML cells, demonstrating that induction of autophagy has a pro-survival effect. Critically, the combination of TKI with inhibitors of autophagy (chloroquine and bafilomycin A1) results in near complete elimination of phenotypically and functionally defined CML stem cells, including CFC and LTC-IC. Together, these findings suggest that autophagy inhibitors will enhance the therapeutic effects of TKI in the treatment of CML. Hydroxychloroquine (HCQ), a less toxic derivative of chloroquine, has been widely used in rheumatology over many years, often at the same time as multiple other drugs. IM now has a 10 year clinical experience and is well tolerated. Here we propose to lead a randomised phase 2 trial with a safety run-in across 3 UK centres in which we will investigate the safety of combining IM with HCQ and compare the efficacy of the combination vesus IM alone in reducing levels of residual disease in CML chronic phase patients who have achieved MCyR after 12 months IM monotherapy but have residual disease as shown by Q-PCR. Patients will be recruited over 24 months, combination treatment will be for 12 months with a further 12 months follow-up.</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>925553</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University College London (UCL), UCL Cancer Institute</gtr:department><gtr:description>autophagy work</gtr:description><gtr:id>17E408E4-000B-4366-8DDC-6C04685DF239</gtr:id><gtr:impact>19363292</gtr:impact><gtr:partnerContribution>Collaborated on paper - Pubmed reference 19363292</gtr:partnerContribution><gtr:piContribution>We have generated a new grant entitled &amp;quot;A randomised phase 2 trial of IM versus HCQ/IM for patients with CML in MCyR with residual disease by Q-PCR&amp;quot; MRC Ref: G0900882</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Thomas Jefferson University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>autophagy work</gtr:description><gtr:id>52722BCD-941D-4FE2-BDE5-573BACBBA48C</gtr:id><gtr:impact>19363292</gtr:impact><gtr:partnerContribution>Collaborated on a paper - Pub med reference 19363292</gtr:partnerContribution><gtr:piContribution>We have generated a new grant entitled &amp;quot;A randomised phase 2 trial of IM versus HCQ/IM for patients with CML in MCyR with residual disease by Q-PCR&amp;quot; MRC Ref: G0900882</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Translational Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Clinical Cancer Medicine</gtr:department><gtr:description>Richard Clark</gtr:description><gtr:id>DCA0284D-C8A4-490A-9844-0E1F7D30FE03</gtr:id><gtr:impact>JCI paper
Kay Kendall grant
MRC grant
MRC DGT sponsorship
CHOICEs TRIAL</gtr:impact><gtr:partnerContribution>enhanced science and clinical trial</gtr:partnerContribution><gtr:piContribution>published JCI paper</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jefferson Medical College</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Department of Cancer Biology</gtr:department><gtr:description>Bruno Calabretta</gtr:description><gtr:id>3A001A65-DC23-48C4-8173-E962AAFC5DDF</gtr:id><gtr:impact>JCi paper
Kay Kendall grant
MRC grant
MRC DGT sponsorship</gtr:impact><gtr:partnerContribution>ENHANCED RESEARCH</gtr:partnerContribution><gtr:piContribution>published JCI paper together</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Department of Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Haematology</gtr:department><gtr:description>David Marin</gtr:description><gtr:id>FAA002CC-CAB7-4278-8639-7E466A064C4E</gtr:id><gtr:impact>JCI paper
Kay Kendall grant
MRC grant
MRC DGT sponsorship</gtr:impact><gtr:partnerContribution>enhanced science and clinical trial</gtr:partnerContribution><gtr:piContribution>PUBLISHED JCI PAPER</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Glasgow</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Beatson Institute for Cancer Research</gtr:department><gtr:description>CRUK</gtr:description><gtr:id>C192D52E-4340-4205-97A8-501C781A99C9</gtr:id><gtr:impact>Nothing as yet</gtr:impact><gtr:partnerContribution>Providing LC3-GFP mouse to cross to BCR-ABL double transgenic mouse. Ed Chan is providing expertise relating to ULK-1</gtr:partnerContribution><gtr:piContribution>We are the leaders of partnership</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Toxicology Unit</gtr:department><gtr:description>Paolo Salmoni</gtr:description><gtr:id>5BA7873D-BD59-4ED2-849F-24EE6077BEBF</gtr:id><gtr:impact>JCI paper
Kay kendall grant
MRC grant
MRC DGT</gtr:impact><gtr:partnerContribution>enhanced science</gtr:partnerContribution><gtr:piContribution>we published the JCI paper together</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Scottish Universities Life Sciences Alliance (SULSA)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>SULSA</gtr:description><gtr:id>A2A78759-1714-4D07-9534-20E5BDE00459</gtr:id><gtr:impact>Still awaitng</gtr:impact><gtr:partnerContribution>Ed Chan is providing expertise relating to ULK-1</gtr:partnerContribution><gtr:piContribution>We are the leaders of the partnership</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>ISEH Amsterdam</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9B049F8F-9B49-4A01-B605-824625D1ABAF</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7C23A765-1162-4101-83F9-1012BB70D449</gtr:id><gtr:impact>500 audience, CML research and clinical run by ESH

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BUSCC University Stem cell seminar Birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AFA3FD73-CAD2-4C5B-A544-25DE57409D21</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Erasmus Haematology Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1FAD2D70-2AD8-434A-AA79-FF41857F6BFC</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beatson Institute for Cancer Research Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF0C002B-ED4E-41A8-88BA-9B6F09903287</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCSF Cancer Centre, San Francisco</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A17BFD4A-3BDF-4CD5-8177-9E0188E1CFCC</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TSCRC Dundee</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D5E400C0-5EAC-44EF-A440-6AB31D597C0D</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA meeting London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3353DA23-D70D-4635-A75A-1CF89F77319B</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>retiral lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>281669CB-7423-4545-9793-D3F039F3253D</gtr:id><gtr:impact>audience around 80, local cytogenetics department for retiral of member of staff

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCMLSG Stockholm</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E8D72FE9-2405-4FF4-A248-903CE400CC1C</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH Portugal</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1100706A-7D2A-4791-A0E5-EFB07E4CB4A4</gtr:id><gtr:impact>Talk with discussion

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4AF7A142-C737-42AE-9CDB-3E954B79178E</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ASH San Diego</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D6E1F3DA-CC13-43EC-B642-CB84CCFF7F22</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKNSCN 4th Annual science meeting York</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0BC85C28-C709-4461-9BD5-32E78C9F49C1</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Society of Haematology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>75DBC307-B7D0-4E77-9216-408C772466AF</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AAAS Vancouver</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B4FD40D3-2D76-4BF1-A5EF-EABC474BD5D7</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TSCRC Dundee</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>890B1E16-B4F8-41B8-B290-BB88E0C7D847</gtr:id><gtr:impact>Talk

Improve collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beatson Institute for Cancer Research, Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>158B2C4C-1C9D-4D36-8AB8-559BEBEC4F49</gtr:id><gtr:impact>talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH Vienna</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>93FA02D7-4472-40F6-A04B-0EB6BB4B0E89</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paterson Institute Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E7AC8EDE-BF91-47C7-9033-FD838C051C89</gtr:id><gtr:impact>talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BUSCC University Stem Cell seminars birmingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>85813949-D676-498C-A5E8-48D974003900</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EHA Amsterdam</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C2BE57FD-7953-4BB9-8204-81FCC5D2E49F</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH Baltimore</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0E7E272D-7FB7-4F61-A2C4-17260A6FCF1B</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CML Professionals Meeting Newcastle</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>44A9946F-D35D-433A-B129-6541D949C918</gtr:id><gtr:impact>CML Professionals Meeting

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>open days for new paul O'Gorman Leukaemia Research centre</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>19449984-2307-443C-8F27-7294580E3011</gtr:id><gtr:impact>9/10 and 22 May 2008. Audience of around 100 at each, short speeches, poster presentations, demon strations in the laboratory

press were present - Sunday Times, Herald articles guest of honour Richard Rockefeller</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UCSF Cancer Centre, San Francisco</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E21A3CA4-FB2E-4EE9-B36E-ADCF24B7EB60</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Paterson Institute Manchester</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A667580-EED0-4625-9FA9-D2E46C5C22DD</gtr:id><gtr:impact>talk

improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ESH Portugal</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6F27AEE3-1F01-4FE6-9E40-ABC3962E04E5</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKNSCN York</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6F085123-3E91-40B1-AB7A-0BA1FD2A2B82</gtr:id><gtr:impact>Talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCMLSG Seminar Stockholm</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>24EB585A-A7C8-4585-97EF-0CEF7A9D79AA</gtr:id><gtr:impact>talk

Improved collaborations</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>19000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>F50B0BE7-4CBD-4FCE-84B0-7D8C2225B4BD</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>833326</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Trial Grant (A randomised phase 2 trial of IM versus HCQ/IM with CML in MCyR with residual disease by Q-PCR)</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>FD8D0AD5-843B-442E-A033-D0471F2B6341</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SULSA</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Scottish Universities Life Sciences Alliance (SULSA)</gtr:fundingOrg><gtr:fundingRef>MSD23_G_Holyoake-Chan</gtr:fundingRef><gtr:id>FB6EB3A6-ABD8-40E1-B2D9-E244E5701519</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novartis</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Novartis</gtr:fundingOrg><gtr:id>0C7EA0D5-1927-44AE-AFC8-CC708466A651</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>training of basic pHd and clinical research fellows</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>2EE0AC34-9608-4406-AE89-B6E243F7D12D</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia NCT01227135</gtr:description><gtr:id>ACA2D3FC-54C1-49C9-8525-9A1950EB8115</gtr:id><gtr:impact>Trial ongoing. No impacts available yet</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Imatinib and Hydroxychloroquine</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN61568166</gtr:ukcrnIsctnId><gtr:url>http://www.controlled-trials.com/ISRCTN61568166</gtr:url><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78FDA7D7-57D6-49B3-BCD3-4E7C592872F7"><gtr:id>78FDA7D7-57D6-49B3-BCD3-4E7C592872F7</gtr:id><gtr:title>Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?</gtr:title><gtr:parentPublicationTitle>Expert review of hematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/71f27e4858bd91991e7a007ab35ab9ea"><gtr:id>71f27e4858bd91991e7a007ab35ab9ea</gtr:id><gtr:otherNames>Mukhopadhyay A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1747-4094</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/45B59E5B-718C-4726-9342-208949FC69E7"><gtr:id>45B59E5B-718C-4726-9342-208949FC69E7</gtr:id><gtr:title>Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35a04edb6a7bdaaaa93878eafd349f8c"><gtr:id>35a04edb6a7bdaaaa93878eafd349f8c</gtr:id><gtr:otherNames>Helgason GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/71D83E1F-F899-403A-B38B-B69057E969D9"><gtr:id>71D83E1F-F899-403A-B38B-B69057E969D9</gtr:id><gtr:title>The chronic myeloid leukemia stem cell: stemming the tide of persistence.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9971b356a7b47c06716ecaedfc78dca8"><gtr:id>9971b356a7b47c06716ecaedfc78dca8</gtr:id><gtr:otherNames>Holyoake TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8B98BDFC-0355-4245-AA3A-CD09D8224519"><gtr:id>8B98BDFC-0355-4245-AA3A-CD09D8224519</gtr:id><gtr:title>ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c7a01af6fd940a650d726a34242cd8b"><gtr:id>9c7a01af6fd940a650d726a34242cd8b</gtr:id><gtr:otherNames>Karvela M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5EC18C43-EEE5-4D68-9C2A-AE8CB3897DF4"><gtr:id>5EC18C43-EEE5-4D68-9C2A-AE8CB3897DF4</gtr:id><gtr:title>Autophagy in chronic myeloid leukaemia: stem cell survival and implication in therapy.</gtr:title><gtr:parentPublicationTitle>Current cancer drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35a04edb6a7bdaaaa93878eafd349f8c"><gtr:id>35a04edb6a7bdaaaa93878eafd349f8c</gtr:id><gtr:otherNames>Helgason GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1568-0096</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/942E4199-9894-4F84-84CE-2C35DFC75A92"><gtr:id>942E4199-9894-4F84-84CE-2C35DFC75A92</gtr:id><gtr:title>Role of autophagy in cancer prevention, development and therapy.</gtr:title><gtr:parentPublicationTitle>Essays in biochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/35a04edb6a7bdaaaa93878eafd349f8c"><gtr:id>35a04edb6a7bdaaaa93878eafd349f8c</gtr:id><gtr:otherNames>Helgason GV</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0071-1365</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/842DF193-3DC2-4857-BC44-489C47DA97DF"><gtr:id>842DF193-3DC2-4857-BC44-489C47DA97DF</gtr:id><gtr:title>Stem Cell Guardians - Old and New Perspectives in LSC Biology.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7b63b5b65b3097b2a5034c842ad8f951"><gtr:id>7b63b5b65b3097b2a5034c842ad8f951</gtr:id><gtr:otherNames>Horne GA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7134AE2F-2947-4115-8ECF-028BC6ECCD22"><gtr:id>7134AE2F-2947-4115-8ECF-028BC6ECCD22</gtr:id><gtr:title>Do we need more drugs for chronic myeloid leukemia?</gtr:title><gtr:parentPublicationTitle>Immunological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9971b356a7b47c06716ecaedfc78dca8"><gtr:id>9971b356a7b47c06716ecaedfc78dca8</gtr:id><gtr:otherNames>Holyoake TL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0105-2896</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C1B3BC9-777F-4A80-BAAA-C2DA4DE72B4A"><gtr:id>9C1B3BC9-777F-4A80-BAAA-C2DA4DE72B4A</gtr:id><gtr:title>Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.</gtr:title><gtr:parentPublicationTitle>Expert review of anticancer therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c7a01af6fd940a650d726a34242cd8b"><gtr:id>9c7a01af6fd940a650d726a34242cd8b</gtr:id><gtr:otherNames>Karvela M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1473-7140</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A5474105-9809-4AE5-A2AB-A27721483BC7"><gtr:id>A5474105-9809-4AE5-A2AB-A27721483BC7</gtr:id><gtr:title>ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/9c7a01af6fd940a650d726a34242cd8b"><gtr:id>9c7a01af6fd940a650d726a34242cd8b</gtr:id><gtr:otherNames>Karvela M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AAF874F2-E92A-4F41-AC7E-1109A30919E4"><gtr:id>AAF874F2-E92A-4F41-AC7E-1109A30919E4</gtr:id><gtr:title>Autophagy in blood cancers: biological role and therapeutic implications.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42679940e74537b9b3b7b8e59ac8c0ba"><gtr:id>42679940e74537b9b3b7b8e59ac8c0ba</gtr:id><gtr:otherNames>Nencioni A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900882</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>